Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “underperform” rating reiterated by analysts at Credit Suisse Group in a research note issued to investors on Monday, November 6th. They currently have a $8.00 price objective on the stock, down from their prior price objective of $14.00. Credit Suisse Group’s price objective would suggest a potential downside of 41.61% from the company’s previous close.
A number of other equities analysts have also issued reports on the stock. Royal Bank Of Canada raised their target price on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the stock an “underperform” rating in a research report on Sunday, November 5th. Piper Jaffray Companies restated a “hold” rating and set a $12.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, November 3rd. Morgan Stanley lowered their target price on shares of Teva Pharmaceutical Industries from $14.00 to $7.00 and set an “underweight” rating on the stock in a research report on Friday, November 3rd. Deutsche Bank AG lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and set a $14.00 target price on the stock. in a research report on Friday, November 3rd. Finally, Wells Fargo & Company lowered shares of Teva Pharmaceutical Industries to a “market perform” rating and lowered their price objective for the company from $17.00 to $11.36 in a research report on Thursday, November 2nd. Seven research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average target price of $21.88.
Teva Pharmaceutical Industries (NYSE:TEVA) traded up $0.23 during mid-day trading on Monday, reaching $13.70. 15,940,000 shares of the company’s stock were exchanged, compared to its average volume of 26,860,000. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.49. The firm has a market capitalization of $14,670.00, a PE ratio of 3.11 and a beta of 0.52.
WARNING: This report was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limiteds-teva-underperform-rating-reaffirmed-at-credit-suisse-group/1762563.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.